In the base case analysis of the whole cohort of HER2-low advanced BC, T-DXd was associated with an increase in the effectiveness of 0.794 QALYs and 1.126 LYs, with an additional cost of $66,583 compared to chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.